Ferdowsi University of Mashhad

Document Type : Research Articles


Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran


In recent years, various efforts have been made to improve the functional potency of cancer drugs. Due to the fact that microRNA in the cell can act as a tumor inhibitor, it can be used as a suitable treatment for most cancers. In this study, chitosan coating is considered a factor that enhances function and effectiveness of microRNAs. MCF-7 cell line was divided into four experimental groups, including an untreated MCF-7 cell group, MCF-7 cell group with miR encapsulated with chitosan, MCF-7 cell group with chitosan, and MCF-7 cell group with doxorubicin as a positive control group. The effect of different concentrations of miR-372 was first evaluated, and the optimal dose was selected to evaluate the following parameters: the induction of cell death by applying flow cytometry, the cell survival by MTT, and the level of P53 protein by immunocytochemistry. The results showed that the dose of 1500 ng/μl of miR-372 coated with chitosan could induce cell death up to 50% in 24 and 72 hours of treatment. In addition, the rate of induction of cell death in the group treated with miR-372 coated with chitosan for 72 hours was statistically significant compared with the control group. In addition, the expression level of P53 protein in the same group was statistically significant compared with the control group. According to the results, the use of cell proliferation cycle regulators such as miR-372 can control the process of proliferation and thus improve the treatment of cancer.


Akbuğa J., Ozbaş-Turan S. and Erdoğan N. (2004) Plasmid-DNA loaded chitosan microspheres for in vitro IL-2 expression. European journal of pharmaceutics and biopharmaceutics 58(3):501-507.
Ascierto M.L., Kmieciak M., Idowu M.O., Manjili R., Zhao Y., Grimes M. et. al. (2012) A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast cancer research and treatment 131(3):871-880.
Bogdanova N., Helbig S. and Dörk T. (2013) Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hereditary cancer in clinical practice 11(1):1-16.
Burstein H.J. and Griggs J.J. (2010) Adjuvant hormonal therapy for early-stage breast cancer. Surgical oncology clinics of North America 19:639-647.
Cai J.,Guan H., Fang L.,Yang Y., Zhu X., Yuan J., et al. (2013) MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. The Journal of clinical investigation 123(2):566-579.
Cheng X.,Chen J. and Huang Z. (2018) miR-372 promotes breast cancer cell proliferation by directly targeting LATS2. Experimental and therapeutic medicine 15(3):2812-2817.
Dunnwald L.K., Rossing M.A. and Li CI. (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast cancer research 9(1):1-10.
Elieh-Ali-Komi, D. and Hamblin M.R. (2016) Chitin and Chitosan: Production and Application of Versatile Biomedical Nanomaterials. International Journal of Advanced Research 4(3):411-427.
Friedman A.E. (2007) Can a single model explain both breast cancer and prostate cancer? Theoretical biology & medical modelling 4(28):28.1-13.
Iorio M.V., Ferracin M., Liu C-G.,Veronese A., Spizzo R., Sabbioni S., et al. (2005) MicroRNA gene xpression deregulation in human breast cancer. Cancer Resarch 65(16):7065-7070.
Krell J., Frampton A.E., Jacob J., Pellegrino L., Roca-Alonso L., Zeloof D., et al. (2012) The clinico-pathologic role of microRNAs miR-9 and miR-151-5p in breast cancer metastasis. Molecular diagnosis & therapy 16(3):167-172.
Majeed W., Aslam B., Javed I., Khaliq T., Muhammad F., Ali A. et al. (2014) Breast cancer: major risk factors and recent developments in treatment. Asian Pacific Journal of Cancer Prevention 15(8):3353-3358.
Osborne C., Wilson P. and Tripathy D. (2004) Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. The oncologist 9(4):361-377.
Özbaş-Turan S. and Akbuğa J. (2011) Plasmid DNA-loaded chitosan/TPP nanoparticles for topical gene delivery. Drug delivery 18(3):215-222.
Paliwal S.R., Paliwal R., Pal H.C., Saxena A.K., Sharma P.R., Gupta P.N., et al. (2012) Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. Molecular pharmaceutics 9(1):176-186.
Regan M.M., Neven P., Giobbie-Hurder A., Goldhirsch A., Ejlertsen B., Mauriac L., et al. (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. The Lancet. Oncology 12(12):1101-1108.
Sharma G.N., Dave R., Sanadya J., Sharma P. and Sharma K. (2010) Various types and management of breast cancer: an overview. Journal of advanced pharmaceutical technology & research 1(2):109-126.
Soliman H. (2013) Immunotherapy Strategies in the Treatment of Breast Cancer. Cancer Control 20(1):17-21.
Velpurisiva P., Gad A., Piel B., Jadia R. and Rai P. (2017) Nanoparticle Design Strategies for Effective Cancer Immunotherapy. Journal of biomedicine 2(2):64-77.
Zhang T., Hu Y., Ju J., Hou L., Li Z., Xiao D., et al. (2016) Downregulation of miR-522 suppresses proliferation and metastasis of non-small cell lung cancer cells by directly targeting DENN/MADD domain containing 2D. Scientific reports 6:1-12.
Zhao Y.X., Liu H.C., Ying W.Y., Wang C.Y., Yu Y.J., Sun W.J., et al. (2017) microRNA-372 inhibits proliferation and induces apoptosis in human breast cancer cells by directly targeting E2F1. Molecular medicine reports 16(6):8069-8075.